Summary

Reducing complications of diabetes mellitus (DM) such as cardiovascular disease (CVD) is a multifaceted dilemma. Several CVD factors are associated with DM, and often, the data that concern these factors conflict. While there are potential concerns about the current approach to drug approval for diabetes medications, there are also valid arguments for retaining the regulatory status quo.